Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have received a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $209.00.

KRYS has been the topic of several recent research reports. Chardan Capital cut their price target on Krystal Biotech from $219.00 to $216.00 and set a “buy” rating on the stock in a report on Friday, August 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $240.00 target price on shares of Krystal Biotech in a research report on Monday, September 15th. Citigroup reissued a “neutral” rating and set a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Finally, Bank of America lowered their price target on shares of Krystal Biotech from $193.00 to $192.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the sale, the insider owned 1,443,276 shares of the company’s stock, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have sold 49,800 shares of company stock valued at $7,487,943. 13.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Crossmark Global Holdings Inc. raised its stake in shares of Krystal Biotech by 2.7% during the first quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company’s stock worth $427,000 after buying an additional 63 shares during the last quarter. Main Management ETF Advisors LLC grew its holdings in Krystal Biotech by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 5,131 shares of the company’s stock worth $705,000 after acquiring an additional 84 shares during the period. M&T Bank Corp raised its position in shares of Krystal Biotech by 2.3% during the 2nd quarter. M&T Bank Corp now owns 3,785 shares of the company’s stock valued at $520,000 after acquiring an additional 85 shares during the last quarter. Xponance Inc. boosted its position in shares of Krystal Biotech by 4.9% in the 1st quarter. Xponance Inc. now owns 1,873 shares of the company’s stock worth $338,000 after purchasing an additional 88 shares during the last quarter. Finally, Sound View Wealth Advisors Group LLC boosted its position in shares of Krystal Biotech by 6.7% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 1,515 shares of the company’s stock worth $273,000 after purchasing an additional 95 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Price Performance

KRYS stock opened at $181.69 on Friday. The firm has a market cap of $5.26 billion, a price-to-earnings ratio of 36.93 and a beta of 0.64. Krystal Biotech has a 1-year low of $122.80 and a 1-year high of $207.84. The firm has a fifty day moving average price of $151.72 and a two-hundred day moving average price of $151.49.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.21. The business had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. As a group, analysts expect that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).